The Department for International Development (DFID) supports malaria vaccine development through the European and Developing Country Clinical Trials Partnership (EDCTP). To date EDCTP has provided €20 million for malaria vaccine development, funding high quality clinical trials to accelerate the process of vaccine development. These trials are necessary to ensure that safe vaccines go beyond discovery and actually enter the market in developing countries.
DFID also supports the Advance Market Commitment (AMC). This funding mechanism, launched by the Prime Minister at the G8 summit, commits governments to fund agreed volumes of as yet unavailable vaccines, at an agreed price, if a product is successfully developed. The first AMC is funding the pneumococcal vaccine. The DFID White Paper, 'Eliminating World Poverty: Building our common future', makes a commitment to consider the funding of malaria vaccine as a possible future AMC.